Disproportionality Analysis of Tirzepatide-Associated Ketoacidosis.
Tirzepatide keeps making headlines in peptide research circles. The latest? A systematic look at ketoacidosis-spectrum events linked to this dual GIP/GLP-1 receptor agonist, pulled from the FDA Adverse Event Reporting System. Researchers at the University of British Columbia dug into every tirzepatide report on record through March 2026 and ran a classic disproportionality analysis.
Endocr Pract
by Frey C
“Disproportionality Analysis of Tirzepatide-Associated Ketoacidosis. Frey C(1). Author information: (1)Department of Medicine, University of British Columbia, Vancouver, British Columbia, Canada. Electronic address: cfrey@bcgsc.ca. BACKGROUND: Tirzepatide, a dual GIP/GLP-1 receptor agonist approved for type 2 diabetes and obesity, has generated post-marketing reports of ketoacidosis-spectrum events. Systematic pharmacovigilance characterization is lacking. METHODS: All tirzepatide reports were extracted from the FDA Adverse Event Reporting System (FAERS) through March 2026. Disproportionality was assessed using the Proportional Reporting Ratio (PRR; signal threshold: PRR ≥ 2, χ2 ≥ 4, n ≥ 3) and Reporting Odds Ratio (ROR) across four MedDRA preferred terms: ketoacidosis NOS, euglycemic DKA, starvation ketoacidosis, and ketosis NOS. RESULTS: Starvation ketoacidosis generated the strongest signal (PRR 70.2, χ2 1560.7; ROR 70.3 [95% CI 46.9-105.2]). Ketosis NOS and euglycemic DKA produced moderate but statistically robust signals meeting all frequentist thresholds (PRR 4.27 and 2.01, respectively). CONCLUSIONS: The starvation ketoacidosis signal is biologically plausible given tirzepatide-mediated appetite suppression and caloric restriction. Euglycemic DKA signals are clinically relevant in peri-operative or dietary restriction contexts. FAERS limitations preclude causal inference. Physicians may consider counseling patients about ketoacidosis symptoms and maintain a low threshold for ketone testing in symptomatic individuals on tirzepatide. Copyright © 2026. Published by Elsevier Inc.”
The big finding: Starvation ketoacidosis stands out with a massive signal (PRR over 70, ROR 70.3). That’s not a rounding error. It’s a real statistical flag, and it lines up with what you’d expect from a compound that slashes appetite and can drive caloric restriction. Ketosis NOS and euglycemic DKA also made the stats sheet, showing moderate but significant signals.
Let’s break it down:
Starvation ketoacidosis: Strongest association with tirzepatide, likely related to appetite suppression effects
Ketosis NOS and euglycemic DKA: Solid signals, especially relevant in situations with restricted calorie intake (think peri-operative or extreme dieting)
All findings come from post-marketing data, so they’re associations, not cause-and-effect
Key takeaway: The biological mechanism makes sense — when you restrict calories fast, ketones can spike. Tirzepatide’s ability to suppress appetite is exactly why researchers and clinicians are so interested in it. These findings don’t undercut that excitement; they just highlight the need for ongoing observation and smart experimental design when studying this peptide.
Want more technical details or sourcing options? Check out the tirzepatide research page or browse the vendor directory for reputable labs.
Tirzepatide research is moving fast, and data like this helps the community refine protocols and keep results reproducible.
Related Reading
The STRIDE Trial and Semaglutide: Implications for Clinical Vascular Practice.
News · J Med ChemStructure-Based Adaptation of a SARS-CoV-2 Neutralizing Peptide to New Virus Variants.
News · J Nucl MedCombining an α(v)β(6)-Targeted (177)Lu-Based Peptide Receptor Radionuclide Therapy with Olaparib to Boost Therapeutic Efficacy in Pancreatic Cancer.
For Research Use Only
All content published on Pushing Peptides is intended for educational and informational purposes only. The information provided is not intended as medical advice, diagnosis, or treatment. Peptides discussed in this article are research compounds and are not approved for human therapeutic use by the FDA or any other regulatory agency. All studies referenced involve animal models or in vitro research unless otherwise stated. Consult a qualified healthcare professional before making any decisions related to your health. Pushing Peptides does not sell peptides — we are a vendor directory and educational resource.